Cargando…

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

BACKGROUND: Dolutegravir recently became the third integrase strand transfer inhibitor (INSTI) approved for use in HIV-1–infected individuals. In contrast to the extensive dataset for HIV-1, in vitro studies and clinical reports of dolutegravir for HIV-2 are limited. To evaluate the potential role o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Robert A, Raugi, Dana N, Pan, Charlotte, Sow, Papa Salif, Seydi, Moussa, Mullins, James I, Gottlieb, Geoffrey S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328052/ https://www.ncbi.nlm.nih.gov/pubmed/25808007 http://dx.doi.org/10.1186/s12977-015-0146-8

Ejemplares similares

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
por: Smith, Robert A., et al.
Publicado: (2023)

HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa
por: Gottlieb, Geoffrey S., et al.
Publicado: (2011)

Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens
por: Smith, Robert A., et al.
Publicado: (2012)

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
por: Ziegler, Robert E., et al.
Publicado: (2018)

Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor
por: Nilavar, Namrata M., et al.
Publicado: (2020)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

Increasing prevalence of hypertension among HIV-positive and negative adults in Senegal, West Africa, 1994-2015
por: Benzekri, Noelle A., et al.
Publicado: (2018)

Correction: Increasing prevalence of hypertension among HIV-positive and negative adults in Senegal, West Africa, 1994-2015
por: Benzekri, Noelle A., et al.
Publicado: (2019)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Infection à VIH-2 au Sénégal: échecs virologiques et résistances aux antirétroviraux (ARV)
por: Ba, Selly, et al.
Publicado: (2019)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
por: Gil, Horacio, et al.
Publicado: (2022)

How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir
por: Das, Atze T., et al.
Publicado: (2018)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
por: Tao, Kaiming, et al.
Publicado: (2023)

Reply to Das and Berkhout, “How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir”
por: Malet, Isabelle, et al.
Publicado: (2018)

Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics
por: DeAnda, Felix, et al.
Publicado: (2013)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
por: Thierry, Eloïse, et al.
Publicado: (2017)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

Synthetic Approaches to a Key Pyridone-carboxylic Acid Precursor Common to the HIV-1 Integrase Strand Transfer Inhibitors Dolutegravir, Bictegravir, and Cabotegravir
por: Mahajan, Pankaj S., et al.
Publicado: (2023)

Transmitted Drug Resistance Against Integrase Strand Transfer Inhibitors in Iranian HIV-Infected Naïve Patients
por: Hashempour, Ava, et al.
Publicado: (2023)

Impact of Traditional Healers on the HIV Care Cascade in Senegal, West Africa: A Longitudinal Study
por: Benzekri, Noelle A., et al.
Publicado: (2021)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Food insecurity predicts loss to follow-up among people living with HIV in Senegal, West Africa
por: Benzekri, Noelle A., et al.
Publicado: (2022)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
por: Vavro, Cindy, et al.
Publicado: (2022)

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018)

Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
por: Hutapea, Hotma Martogi Lorensi, et al.
Publicado: (2018)

Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding
por: Chitongo, Rumbidzai, et al.
Publicado: (2020)

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis
por: Ngoufack Jagni Semengue, Ezechiel, et al.
Publicado: (2022)

Women hold up half the sky – and half the burden of the HIV epidemic
por: Heidari, Shirin, et al.
Publicado: (2013)

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)

The impact of food insecurity on HIV outcomes in Senegal, West Africa: a prospective longitudinal study
por: Benzekri, Noelle A., et al.
Publicado: (2021)

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors
por: Ni, Xiaoju, et al.
Publicado: (2012)

Has the world ceased to care about HIV? And what can we do about it?
por: Wainberg, Mark A, et al.
Publicado: (2015)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
por: Koneru, Pratibha C, et al.
Publicado: (2019)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Patterns of resistance development with integrase inhibitors in HIV
por: Mbisa, Jean L, et al.
Publicado: (2011)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jk5o02mfecio1g0ov2lmrl4tdr